Search Results

You are looking at 61 - 70 of 177 items for :

  • "cetuximab" x
  • All content x
Clear All
Full access

Presenter: Dustin A. Deming

encorafenib/binimetinib/cetuximab, and median PFS was 8 months. These data led to an update to the NCCN Guidelines for patients with BRAF V600–mutated disease, although an update of that study concluded that binimetinib is not a necessary component. 10 The

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, and Deborah A. Freedman-Cass

show a synergistic effect of such dual inhibition. 41 , 42 However, vemurafenib in combination with cetuximab- or panitumumab-based therapy has been ineffective in early clinical trials. 43 Results from preclinical and early clinical studies suggest

Full access

NCCN Guidelines Insights: Rectal Cancer, Version 6.2020

Featured Updates to the NCCN Guidelines

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Alyse Johnson-Chilla, and Lisa A. Gurski

antibodies (cetuximab or panitumumab) have been included in the guidelines for RAS wild-type mCRC for more than a decade, the number of biomarker-targeted therapies recommended for mCRC has substantially expanded in recent versions, now including checkpoint

Full access

John G. Phillips, Theodore S. Hong, and David P. Ryan

patients with metastatic colorectal cancer. 48 , 49 Two types of EGFR-targeted therapies have been developed and studied in rectal cancer: monoclonal antibodies that target the extracellular domain (eg, cetuximab and panitumumab) and small molecule

Full access

Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin

reservoir in patients with tumors of the mid or lower rectum. Targeted Therapies Cetuximab/panitumumab and bevacizumab have been approved for use in patients with metastatic colorectal cancer. Naturally, these agents are currently being investigated

Full access

David G. Pfister, Sharon Spencer, David Adelstein, Douglas Adkins, Yoshimi Anzai, David M. Brizel, Justine Y. Bruce, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, David W. Eisele, Moon Fenton, Robert L. Foote, Thomas Galloway, Maura L. Gillison, Robert I. Haddad, Wesley L. Hicks Jr., Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Ellie Maghami, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, James W. Rocco, Cristina P. Rodriguez, Jatin P. Shah, Randal S. Weber, Gregory Weinstein, Matthew Witek, Frank Worden, Sue S. Yom, Weining Zhen, Jennifer L. Burns, and Susan D. Darlow

antibody cetuximab. Bonner et al 159 randomly assigned 424 patients with locally advanced stage III to IV squamous cell carcinomas of the hypopharynx, oropharynx, and larynx to receive definitive RT with or without cetuximab. Locoregional control and

Full access

Barbara Burtness

assortment of adverse skin effects are associated with the use of epidermal growth factor receptor (EGFR) inhibitors such as cetuximab and erlotinib. Although papulopustular rash may be the most commonly observed side effect of these targeted agents, non

Full access

/or Lung Metastasis Only FOLFOX + cetuximab removed as a treatment option. Adjuvant Therapy for Resectable Synchronous Liver and/or Lung Metastasis Only Recommendations following “colectomy, with synchronous or staged liver or lung

Full access

Paul F. Engstrom

vasculature through an anti–vascular endothelial growth factor effect, and enhanced first-line FOLFOX in the treatment of patients with metastatic disease. That same year, cetuximab, a chimeric antibody, and its congener, panitumumab, a fully humanized

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett

metastatic colorectal cancer patients treated with cetuximab . J Clin Oncol 2007 ; 25 : 3230 – 3237 . 27 De Roock W Piessevaux H De Schutter J . KRAS wild-type state predicts survival and is associated to early radiological response in